<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-10-20" updated="2019-12-02">
  <drugbank-id primary="true">DB11973</drugbank-id>
  <drugbank-id>DB05007</drugbank-id>
  <name>Tesevatinib</name>
  <description>Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.&#13;
&#13;
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.</description>
  <cas-number>781613-23-8</cas-number>
  <unii>F6XM2TN5A1</unii>
  <average-mass>491.39</average-mass>
  <monoisotopic-mass>490.1338596</monoisotopic-mass>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action>Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>50-70 hours</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.</description>
    <direct-parent>Quinazolinamines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Diazanaphthalenes</class>
    <subclass>Benzodiazines</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Aminopyrimidines and derivatives</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Anisoles</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Aryl fluorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Dichlorobenzenes</alternative-parent>
    <alternative-parent>Fluorobenzenes</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>N-alkylpyrrolidines</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary amines</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>1,2-dichlorobenzene</substituent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Amine</substituent>
    <substituent>Aminopyrimidine</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Anisole</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Chlorobenzene</substituent>
    <substituent>Ether</substituent>
    <substituent>Fluorobenzene</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-alkylpyrrolidine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Quinazolinamine</substituent>
    <substituent>Secondary amine</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">TESEVATINIB</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Aza Compounds</category>
      <mesh-id>D001372</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>ErbB Receptors, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Protein Kinase Inhibitors</category>
      <mesh-id>D047428</mesh-id>
    </category>
    <category>
      <category>Receptor, EphB4, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Receptor, ErbB-2, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tyrosine Kinase Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vascular Endothelial Growth Factor Receptor-2, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Acetaminophen can be increased when it is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The serum concentration of Propacetamol can be increased when it is combined with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>The therapeutic efficacy of Salmon Calcitonin can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00066</drugbank-id>
      <name>Follitropin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The therapeutic efficacy of Carbimazole can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The therapeutic efficacy of Methimazole can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The therapeutic efficacy of Liotrix can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>The therapeutic efficacy of Tiratricol can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05084</drugbank-id>
      <name>Abaloparatide</name>
      <description>The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05829</drugbank-id>
      <name>Parathyroid hormone</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06285</drugbank-id>
      <name>Teriparatide</name>
      <description>The therapeutic efficacy of Teriparatide can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09421</drugbank-id>
      <name>Protirelin</name>
      <description>The therapeutic efficacy of Protirelin can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12629</drugbank-id>
      <name>3,5-diiodothyropropionic acid</name>
      <description>The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13742</drugbank-id>
      <name>Elcatonin</name>
      <description>The therapeutic efficacy of Elcatonin can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15263</drugbank-id>
      <name>Thyrotropin</name>
      <description>The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.51</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.76e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>5.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>7-{[(3aR,5S,6aS)-2-methyl-octahydrocyclopenta[c]pyrrol-5-yl]methoxy}-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>7-{[(3aR,5S,6aS)-2-methyl-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy}-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>491.39</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>490.1338596</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC1=C(OC[C@H]2C[C@H]3CN(C)C[C@H]3C2)C=C2N=CN=C(NC3=CC=C(Cl)C(Cl)=C3F)C2=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C24H25Cl2FN4O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13-,14-,15+</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>HVXKQKFEHMGHSL-QKDCVEJESA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>59.51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>127.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.01</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>10458325</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347828296</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>32699556</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tesevatinib</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3544983</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000953</id>
      <name>Pro-epidermal growth factor</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P01133" source="Swiss-Prot">
        <name>Pro-epidermal growth factor</name>
        <general-function>Transmembrane receptor protein tyrosine kinase activator activity</general-function>
        <specific-function>EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941).</specific-function>
        <gene-name>EGF</gene-name>
        <locus>4q25</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>1033-1053</transmembrane-regions>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>5.74</theoretical-pi>
        <molecular-weight>133993.12</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3229</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>EGF</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X04571</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31121</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P01133</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EGF_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>EGF</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037104|Pro-epidermal growth factor
MLLTLIILLPVVSKFSFVSLSAPQHWSCPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRID
TEGTNYEQLVVDAGVSVIMDFHYNEKRIYWVDLERQLLQRVFLNGSRQERVCNIEKNVSG
MAINWINEEVIWSNQQEGIITVTDMKGNNSHILLSALKYPANVAVDPVERFIFWSSEVAG
SLYRADLDGVGVKALLETSEKITAVSLDVLDKRLFWIQYNREGSNSLICSCDYDGGSVHI
SKHPTQHNLFAMSLFGDRIFYSTWKMKTIWIANKHTGKDMVRINLHSSFVPLGELKVVHP
LAQPKAEDDTWEPEQKLCKLRKGNCSSTVCGQDLQSHLCMCAEGYALSRDRKYCEDVNEC
AFWNHGCTLGCKNTPGSYYCTCPVGFVLLPDGKRCHQLVSCPRNVSECSHDCVLTSEGPL
CFCPEGSVLERDGKTCSGCSSPDNGGCSQLCVPLSPVSWECDCFPGYDLQLDEKSCAASG
PQPFLLFANSQDIRHMHFDGTDYGTLLSQQMGMVYALDHDPVENKIYFAHTALKWIERAN
MDGSQRERLIEEGVDVPEGLAVDWIGRRFYWTDRGKSLIGRSDLNGKRSKIITKENISQP
RGIAVHPMAKRLFWTDTGINPRIESSSLQGLGRLVIASSDLIWPSGITIDFLTDKLYWCD
AKQSVIEMANLDGSKRRRLTQNDVGHPFAVAVFEDYVWFSDWAMPSVMRVNKRTGKDRVR
LQGSMLKPSSLVVVHPLAKPGADPCLYQNGGCEHICKKRLGTAWCSCREGFMKASDGKTC
LALDGHQLLAGGEVDLKNQVTPLDILSKTRVSEDNITESQHMLVAEIMVSDQDDCAPVGC
SMYARCISEGEDATCQCLKGFAGDGKLCSDIDECEMGVPVCPPASSKCINTEGGYVCRCS
EGYQGDGIHCLDIDECQLGEHSCGENASCTNTEGGYTCMCAGRLSEPGLICPDSTPPPHL
REDDHHYSVRNSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWW
ELRHAGHGQQQKVIVVAVCVVVLVMLLLLSLWGAHYYRTQKLLSKNPKNPYEESSRDVRS
RRPADTEDGMSSCPQPWFVVIKEHQDLKNGGQPVAGEDGQAADGSMQPTSWRQEPQLCGM
GTEQGCWIPVSSDKGSCPQVMERSFHMPSYGTQTLEGGVEKPHSLLSANPLWQQRALDPP
HQMELTQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019041|Pro-epidermal growth factor (EGF)
ATGCTGCTCACTCTTATCATTCTGTTGCCAGTAGTTTCAAAATTTAGTTTTGTTAGTCTC
TCAGCACCGCAGCACTGGAGCTGTCCTGAAGGTACTCTCGCAGGAAATGGGAATTCTACT
TGTGTGGGTCCTGCACCCTTCTTAATTTTCTCCCATGGAAATAGTATCTTTAGGATTGAC
ACAGAAGGAACCAATTATGAGCAATTGGTGGTGGATGCTGGTGTCTCAGTGATCATGGAT
TTTCATTATAATGAGAAAAGAATCTATTGGGTGGATTTAGAAAGACAACTTTTGCAAAGA
GTTTTTCTGAATGGGTCAAGGCAAGAGAGAGTATGTAATATAGAGAAAAATGTTTCTGGA
ATGGCAATAAATTGGATAAATGAAGAAGTTATTTGGTCAAATCAACAGGAAGGAATCATT
ACAGTAACAGATATGAAAGGAAATAATTCCCACATTCTTTTAAGTGCTTTAAAATATCCT
GCAAATGTAGCAGTTGATCCAGTAGAAAGGTTTATATTTTGGTCTTCAGAGGTGGCTGGA
AGCCTTTATAGAGCAGATCTCGATGGTGTGGGAGTGAAGGCTCTGTTGGAGACATCAGAG
AAAATAACAGCTGTGTCATTGGATGTGCTTGATAAGCGGCTGTTTTGGATTCAGTACAAC
AGAGAAGGAAGCAATTCTCTTATTTGCTCCTGTGATTATGATGGAGGTTCTGTCCACATT
AGTAAACATCCAACACAGCATAATTTGTTTGCAATGTCCCTTTTTGGTGACCGTATCTTC
TATTCAACATGGAAAATGAAGACAATTTGGATAGCCAACAAACACACTGGAAAGGACATG
GTTAGAATTAACCTCCATTCATCATTTGTACCACTTGGTGAACTGAAAGTAGTGCATCCA
CTTGCACAACCCAAGGCAGAAGATGACACTTGGGAGCCTGAGCAGAAACTTTGCAAATTG
AGGAAAGGAAACTGCAGCAGCACTGTGTGTGGGCAAGACCTCCAGTCACACTTGTGCATG
TGTGCAGAGGGATACGCCCTAAGTCGAGACCGGAAGTACTGTGAAGATGTTAATGAATGT
GCTTTTTGGAATCATGGCTGTACTCTTGGGTGTAAAAACACCCCTGGATCCTATTACTGC
ACGTGCCCTGTAGGATTTGTTCTGCTTCCTGATGGGAAACGATGTCATCAACTTGTTTCC
TGTCCACGCAATGTGTCTGAATGCAGCCATGACTGTGTTCTGACATCAGAAGGTCCCTTA
TGTTTCTGTCCTGAAGGCTCAGTGCTTGAGAGAGATGGGAAAACATGTAGCGGTTGTTCC
TCACCCGATAATGGTGGATGTAGCCAGCTCTGCGTTCCTCTTAGCCCAGTATCCTGGGAA
TGTGATTGCTTTCCTGGGTATGACCTACAACTGGATGAAAAAAGCTGTGCAGCTTCAGGA
CCACAACCATTTTTGCTGTTTGCCAATTCTCAAGATATTCGACACATGCATTTTGATGGA
ACAGACTATGGAACTCTGCTCAGCCAGCAGATGGGAATGGTTTATGCCCTAGATCATGAC
CCTGTGGAAAATAAGATATACTTTGCCCATACAGCCCTGAAGTGGATAGAGAGAGCTAAT
ATGGATGGTTCCCAGCGAGAAAGGCTTATTGAGGAAGGAGTAGATGTGCCAGAAGGTCTT
GCTGTGGACTGGATTGGCCGTAGATTCTATTGGACAGACAGAGGGAAATCTCTGATTGGA
AGGAGTGATTTAAATGGGAAACGTTCCAAAATAATCACTAAGGAGAACATCTCTCAACCA
CGAGGAATTGCTGTTCATCCAATGGCCAAGAGATTATTCTGGACTGATACAGGGATTAAT
CCACGAATTGAAAGTTCTTCCCTCCAAGGCCTTGGCCGTCTGGTTATAGCCAGCTCTGAT
CTAATCTGGCCCAGTGGAATAACGATTGACTTCTTAACTGACAAGTTGTACTGGTGCGAT
GCCAAGCAGTCTGTGATTGAAATGGCCAATCTGGATGGTTCAAAACGCCGAAGACTTACC
CAGAATGATGTAGGTCACCCATTTGCTGTAGCAGTGTTTGAGGATTATGTGTGGTTCTCA
GATTGGGCTATGCCATCAGTAATGAGAGTAAACAAGAGGACTGGCAAAGATAGAGTACGT
CTCCAAGGCAGCATGCTGAAGCCCTCATCACTGGTTGTGGTTCATCCATTGGCAAAACCA
GGAGCAGATCCCTGCTTATATCAAAACGGAGGCTGTGAACATATTTGCAAAAAGAGGCTT
GGAACTGCTTGGTGTTCGTGTCGTGAAGGTTTTATGAAAGCCTCAGATGGGAAAACGTGT
CTGGCTCTGGATGGTCATCAGCTGTTGGCAGGTGGTGAAGTTGATCTAAAGAACCAAGTA
ACACCATTGGACATCTTGTCCAAGACTAGAGTGTCAGAAGATAACATTACAGAATCTCAA
CACATGCTAGTGGCTGAAATCATGGTGTCAGATCAAGATGACTGTGCTCCTGTGGGATGC
AGCATGTATGCTCGGTGTATTTCAGAGGGAGAGGATGCCACATGTCAGTGTTTGAAAGGA
TTTGCTGGGGATGGAAAACTATGTTCTGATATAGATGAATGTGAGATGGGTGTCCCAGTG
TGCCCCCCTGCCTCCTCCAAGTGCATCAACACCGAAGGTGGTTATGTCTGCCGGTGCTCA
GAAGGCTACCAAGGAGATGGGATTCACTGTCTTGACTCTACTCCACCCCCTCACCTCAGG
GAAGATGACCACCACTATTCCGTAAGAAATAGTGACTCTGAATGTCCCCTGTCCCACGAT
GGGTACTGCCTCCATGATGGTGTGTGCATGTATATTGAAGCATTGGACAAGTATGCATGC
AACTGTGTTGTTGGCTACATCGGGGAGCGATGTCAGTACCGAGACCTGAAGTGGTGGGAA
CTGCGCCACGCTGGCCACGGGCAGCAGCAGAAGGTCATCGTGGTGGCTGTCTGCGTGGTG
GTGCTTGTCATGCTGCTCCTCCTGAGCCTGTGGGGGGCCCACTACTACAGGACTCAGAAG
CTGCTATCGAAAAACCCAAAGAATCCTTATGAGGAGTCGAGCAGAGATGTGAGGAGTCGC
AGGCCTGCTGACACTGAGGATGGGATGTCCTCTTGCCCTCAACCTTGGTTTGTGGTTATA
AAAGAACACCAAGACCTCAAGAATGGGGGTCAACCAGTGGCTGGTGAGGATGGCCAGGCA
GCAGATGGGTCAATGCAACCAACTTCATGGAGGCAGGAGCCCCAGTTATGTGGAATGGGC
ACAGAGCAAGGCTGCTGGATTCCAGTATCCAGTGATAAGGGCTCCTGTCCCCAGGTAATG
GAGCGAAGCTTTCATATGCCCTCCTATGGGACACAGACCCTTGAAGGGGGTGTCGAGAAG
CCCCATTCTCTCCTATCAGCTAACCCATTATGGCAACAAAGGGCCCTGGACCCACCACAC
CAAATGGAGCTGACTCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00008</identifier>
            <name>EGF</name>
          </pfam>
          <pfam>
            <identifier>PF07645</identifier>
            <name>EGF_CA</name>
          </pfam>
          <pfam>
            <identifier>PF00058</identifier>
            <name>Ldl_recept_b</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epidermal growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>growth factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane receptor protein tyrosine kinase activator activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of transmembrane receptor protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>branching morphogenesis of an epithelial tube</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland alveolus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cholesterol efflux</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of catenin import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cerebellar granule cell precursor proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epidermal growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of hyaluronan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-threonine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein localization to cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>STAT protein import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0002453</id>
      <name>Ephrin type-B receptor 4</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P54760" source="Swiss-Prot">
        <name>Ephrin type-B receptor 4</name>
        <general-function>Transmembrane receptor protein tyrosine kinase activity</general-function>
        <specific-function>Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. EPHB4-mediated forward signaling controls cellular repulsion and segregation form EFNB2-expressing cells. Plays also a role in postnatal blood vessel remodeling, morphogenesis and permeability and is thus important in the context of tumor angiogenesis.</specific-function>
        <gene-name>EPHB4</gene-name>
        <locus>7q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>540-560</transmembrane-regions>
        <signal-regions>1-15</signal-regions>
        <theoretical-pi>6.89</theoretical-pi>
        <molecular-weight>108269.26</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3395</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>EPHB4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U07695</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1833</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P54760</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EPHB4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.10.1</synonym>
          <synonym>Hepatoma transmembrane kinase</synonym>
          <synonym>HTK</synonym>
          <synonym>MYK1</synonym>
          <synonym>TYRO11</synonym>
          <synonym>Tyrosine-protein kinase TYRO11</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004817|Ephrin type-B receptor 4
MELRVLLCWASLAAALEETLLNTKLETADLKWVTFPQVDGQWEELSGLDEEQHSVRTYEV
CDVQRAPGQAHWLRTGWVPRRGAVHVYATLRFTMLECLSLPRAGRSCKETFTVFYYESDA
DTATALTPAWMENPYIKVDTVAAEHLTRKRPGAEATGKVNVKTLRLGPLSKAGFYLAFQD
QGACMALLSLHLFYKKCAQLTVNLTRFPETVPRELVVPVAGSCVVDAVPAPGPSPSLYCR
EDGQWAEQPVTGCSCAPGFEAAEGNTKCRACAQGTFKPLSGEGSCQPCPANSHSNTIGSA
VCQCRVGYFRARTDPRGAPCTTPPSAPRSVVSRLNGSSLHLEWSAPLESGGREDLTYALR
CRECRPGGSCAPCGGDLTFDPGPRDLVEPWVVVRGLRPDFTYTFEVTALNGVSSLATGPV
PFEPVNVTTDREVPPAVSDIRVTRSSPSSLSLAWAVPRAPSGAVLDYEVKYHEKGAEGPS
SVRFLKTSENRAELRGLKRGASYLVQVRARSEAGYGPFGQEHHSQTQLDESEGWREQLAL
IAGTAVVGVVLVLVVIVVAVLCLRKQSNGREAEYSDKHGQYLIGHGTKVYIDPFTYEDPN
EAVREFAKEIDVSYVKIEEVIGAGEFGEVCRGRLKAPGKKESCVAIKTLKGGYTERQRRE
FLSEASIMGQFEHPNIIRLEGVVTNSMPVMILTEFMENGALDSFLRLNDGQFTVIQLVGM
LRGIASGMRYLAEMSYVHRDLAARNILVNSNLVCKVSDFGLSRFLEENSSDPTYTSSLGG
KIPIRWTAPEAIAFRKFTSASDAWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLP
PPPDCPTSLHQLMLDCWQKDRNARPRFPQVVSALDKMIRNPASLKIVARENGGASHPLLD
QRQPHYSAFGSVGEWLRAIKMGRYEESFAAAGFGSFELVSQISAEDLLRIGVTLAGHQKK
ILASVQHMKSQAKPGTPGGTGGPAPQY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016795|Ephrin type-B receptor 4 (EPHB4)
ATGGAGCTCCGGGTGCTGCTCTGCTGGGCTTCGTTGGCCGCAGCTTTGGAAGAGACCCTG
CTGAACACAAAATTGGAAACTGCTGATCTGAAGTGGGTGACATTCCCTCAGGTGGACGGG
CAGTGGGAGGAACTGAGCGGCCTGGATGAGGAACAGCACAGCGTGCGCACCTACGAAGTG
TGTGACGTGCAGCGTGCCCCGGGCCAGGCCCACTGGCTTCGCACAGGTTGGGTCCCACGG
CGGGGCGCCGTCCACGTGTACGCCACGCTGCGCTTCACCATGCTCGAGTGCCTGTCCCTG
CCTCGGGCTGGGCGCTCCTGCAAGGAGACCTTCACCGTCTTCTACTATGAGAGCGATGCG
GACACGGCCACGGCCCTCACGCCAGCCTGGATGGAGAACCCCTACATCAAGGTGGACACG
GTGGCCGCGGAGCATCTCACCCGGAAGCGCCCTGGGGCCGAGGCCACCGGGAAGGTGAAT
GTCAAGACGCTGCGTCTGGGACCGCTCAGCAAGGCTGGCTTCTACCTGGCCTTCCAGGAC
CAGGGTGCCTGCATGGCCCTGCTATCCCTGCACCTCTTCTACAAAAAGTGCGCCCAGCTG
ACTGTGAACCTGACTCGATTCCCGGAGACTGTGCCTCGGGAGCTGGTTGTGCCCGTGGCC
GGTAGCTGCGTGGTGGATGCCGTCCCCGCCCCTGGCCCCAGCCCCAGCCTCTACTGCCGT
GAGGATGGCCAGTGGGCCGAACAGCCGGTCACGGGCTGCAGCTGTGCTCCGGGGTTCGAG
GCAGCTGAGGGGAACACCAAGTGCCGAGCCTGTGCCCAGGGCACCTTCAAGCCCCTGTCA
GGAGAAGGGTCCTGCCAGCCATGCCCAGCCAATAGCCACTCTAACACCATTGGATCAGCC
GTCTGCCAGTGCCGCGTCGGGTACTTCCGGGCACGCACAGACCCCCGGGGTGCACCCTGC
ACCACCCCTCCTTCGGCTCCGCGGAGCGTGGTTTCCCGCCTGAACGGCTCCTCCCTGCAC
CTGGAATGGAGTGCCCCCCTGGAGTCTGGTGGCCGAGAGGACCTCACCTACGCCCTCCGC
TGCCGGGAGTGCCGACCCGGAGGCTCCTGTGCGCCCTGCGGGGGAGACCTGACTTTTGAC
CCCGGCCCCCGGGACCTGGTGGAGCCCTGGGTGGTGGTTCGAGGGCTACGTCCTGACTTC
ACCTATACCTTTGAGGTCACTGCATTGAACGGGGTATCCTCCTTAGCCACGGGGCCCGTC
CCATTTGAGCCTGTCAATGTCACCACTGACCGAGAGGTACCTCCTGCAGTGTCTGACATC
CGGGTGACGCGGTCCTCACCCAGCAGCTTGAGCCTGGCCTGGGCTGTTCCCCGGGCACCC
AGTGGGGCTGTGCTGGACTACGAGGTCAAATACCATGAGAAGGGCGCCGAGGGTCCCAGC
AGCGTGCGGTTCCTGAAGACGTCAGAAAACCGGGCAGAGCTGCGGGGGCTGAAGCGGGGA
GCCAGCTACCTGGTGCAGGTACGGGCGCGCTCTGAGGCCGGCTACGGGCCCTTCGGCCAG
GAACATCACAGCCAGACCCAACTGGATGAGAGCGAGGGCTGGCGGGAGCAGCTGGCCCTG
ATTGCGGGCACGGCAGTCGTGGGTGTGGTCCTGGTCCTGGTGGTCATTGTGGTCGCAGTT
CTCTGCCTCAGGAAGCAGAGCAATGGGAGAGAAGCAGAATATTCGGACAAACACGGACAG
TATCTCATCGGACATGGTACTAAGGTCTACATCGACCCCTTCACTTATGAAGACCCTAAT
GAGGCTGTGAGGGAATTTGCAAAAGAGATCGATGTCTCCTACGTCAAGATTGAAGAGGTG
ATTGGTGCAGGTGAGTTTGGCGAGGTGTGCCGGGGGCGGCTCAAGGCCCCAGGGAAGAAG
GAGAGCTGTGTGGCAATCAAGACCCTGAAGGGTGGCTACACGGAGCGGCAGCGGCGTGAG
TTTCTGAGCGAGGCCTCCATCATGGGCCAGTTCGAGCACCCCAATATCATCCGCCTGGAG
GGCGTGGTCACCAACAGCATGCCCGTCATGATTCTCACAGAGTTCATGGAGAACGGCGCC
CTGGACTCCTTCCTGCGGCTAAACGACGGACAGTTCACAGTCATCCAGCTCGTGGGCATG
CTGCGGGGCATCGCCTCGGGCATGCGGTACCTTGCCGAGATGAGCTACGTCCACCGAGAC
CTGGCTGCTCGCAACATCCTAGTCAACAGCAACCTCGTCTGCAAAGTGTCTGACTTTGGC
CTTTCCCGATTCCTGGAGGAGAACTCTTCCGATCCCACCTACACGAGCTCCCTGGGAGGA
AAGATTCCCATCCGATGGACTGCCCCGGAGGCCATTGCCTTCCGGAAGTTCACTTCCGCC
AGTGATGCCTGGAGTTACGGGATTGTGATGTGGGAGGTGATGTCATTTGGGGAGAGGCCG
TACTGGGACATGAGCAATCAGGACGTGATCAATGCCATTGAACAGGACTACCGGCTGCCC
CCGCCCCCAGACTGTCCCACCTCCCTCCACCAGCTCATGCTGGACTGTTGGCAGAAAGAC
CGGAATGCCCGGCCCCGCTTCCCCCAGGTGGTCAGCGCCCTGGACAAGATGATCCGGAAC
CCCGCCAGCCTCAAAATCGTGGCCCGGGAGAATGGCGGGGCCTCACACCCTCTCCTGGAC
CAGCGGCAGCCTCACTACTCAGCTTTTGGCTCTGTGGGCGAGTGGCTTCGGGCCATCAAA
ATGGGAAGATACGAAGAAAGTTTCGCAGCCGCTGGCTTTGGCTCCTTCGAGCTGGTCAGC
CAGATCTCTGCTGAGGACCTGCTCCGAATCGGAGTCACTCTGGCGGGACACCAGAAGAAA
ATCTTGGCCAGTGTCCAGCACATGAAGTCCCAGGCCAAGCCGGGAACCCCGGGTGGGACA
GGAGGACCGGCCCCGCAGTACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07714</identifier>
            <name>Pkinase_Tyr</name>
          </pfam>
          <pfam>
            <identifier>PF00041</identifier>
            <name>fn3</name>
          </pfam>
          <pfam>
            <identifier>PF01404</identifier>
            <name>Ephrin_lbd</name>
          </pfam>
          <pfam>
            <identifier>PF00536</identifier>
            <name>SAM_1</name>
          </pfam>
          <pfam>
            <identifier>PF14575</identifier>
            <name>EphA2_TM</name>
          </pfam>
          <pfam>
            <identifier>PF07699</identifier>
            <name>Ephrin_rec_like</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ephrin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane receptor protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell migration involved in sprouting angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ephrin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autophosphorylation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000511</id>
      <name>Receptor tyrosine-protein kinase erbB-2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04626" source="Swiss-Prot">
        <name>Receptor tyrosine-protein kinase erbB-2</name>
        <general-function>Transmembrane signaling receptor activity</general-function>
        <specific-function>Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.</specific-function>
        <gene-name>ERBB2</gene-name>
        <locus>17q11.2-q12|17q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>653-675</transmembrane-regions>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>5.76</theoretical-pi>
        <molecular-weight>137909.27</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3430</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ERBB2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M11767</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>553282</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04626</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ERBB2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.10.1</synonym>
          <synonym>HER2</synonym>
          <synonym>Metastatic lymph node gene 19 protein</synonym>
          <synonym>MLN 19</synonym>
          <synonym>MLN19</synonym>
          <synonym>NEU</synonym>
          <synonym>NGL</synonym>
          <synonym>p185erbB2</synonym>
          <synonym>Proto-oncogene c-ErbB-2</synonym>
          <synonym>Proto-oncogene Neu</synonym>
          <synonym>Tyrosine kinase-type cell surface receptor HER2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001020|Receptor tyrosine-protein kinase erbB-2
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010360|Receptor tyrosine-protein kinase erbB-2 (ERBB2)
ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTAC
CAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGC
CTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAA
GTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGAC
AACTATGCCCTGGCCGTGCTAGACAATGGAGACCCGCTGAACAATACCACCCCTGTCACA
GGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTCGAAGCCTCACAGAGATCTTGAAA
GGAGGGGTCTTGATCCAGCGGAACCCCCAGCTCTGCTACCAGGACACGATTTTGTGGAAG
GACATCTTCCACAAGAACAACCAGCTGGCTCTCACACTGATAGACACCAACCGCTCTCGG
GCCTGCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAG
GATTGTCAGAGCCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGCCA
CTGCCCACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTCT
GACTGCCTGGCCTGCCTCCACTTCAACCACAGTGGCATCTGTGAGCTGCACTGCCCAGCC
CTGGTCACCTACAACACAGACACGTTTGAGTCCATGCCCAATCCCGAGGGCCGGTATACA
TTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACAACTACCTTTCTACGGACGTGGGATCC
TGCACCCTCGTCTGCCCCCTGCACAACCAAGAGGTGACAGCAGAGGATGGAACACAGCGG
TGTGAGAAGTGCAGCAAGCCCTGTGCCCGAGTGTGCTATGGTCTGGGCATGGAGCACTTG
CGAGAGGTGAGGGCAGTTACCAGTGCCAATATCCAGGAGTTTGCTGGCTGCAAGAAGATC
TTTGGGAGCCTGGCATTTCTGCCGGAGAGCTTTGATGGGGACCCAGCCTCCAACACTGCC
CCGCTCCAGCCAGAGCAGCTCCAAGTGTTTGAGACTCTGGAAGAGATCACAGGTTACCTA
TACATCTCAGCATGGCCGGACAGCCTGCCTGACCTCAGCGTCTTCCAGAACCTGCAAGTA
ATCCGGGGACGAATTCTGCACAATGGCGCCTACTCGCTGACCCTGCAAGGGCTGGGCATC
AGCTGGCTGGGGCTGCGCTCACTGAGGGAACTGGGCAGTGGACTGGCCCTCATCCACCAT
AACACCCACCTCTGCTTCGTGCACACGGTGCCCTGGGACCAGCTCTTTCGGAACCCGCAC
CAAGCTCTGCTCCACACTGCCAACCGGCCAGAGGACGAGTGTGTGGGCGAGGGCCTGGCC
TGCCACCAGCTGTGCGCCCGAGGGCACTGCTGGGGTCCAGGGCCCACCCAGTGTGTCAAC
TGCAGCCAGTTCCTTCGGGGCCAGGAGTGCGTGGAGGAATGCCGAGTACTGCAGGGGCTC
CCCAGGGAGTATGTGAATGCCAGGCACTGTTTGCCGTGCCACCCTGAGTGTCAGCCCCAG
AATGGCTCAGTGACCTGTTTTGGACCGGAGGCTGACCAGTGTGTGGCCTGTGCCCACTAT
AAGGACCCTCCCTTCTGCGTGGCCCGCTGCCCCAGCGGTGTGAAACCTGACCTCTCCTAC
ATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCGCATGCCAGCCTTGCCCCATCAACTGC
ACCCACTCCTGTGTGGACCTGGATGACAAGGGCTGCCCCGCCGAGCAGAGAGCCAGCCCT
CTGACGTCCATCATCTCTGCGGTGGTTGGCATTCTGCTGGTCGTGGTCTTGGGGGTGGTC
TTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATCCGGAAGTACACGATGCGGAGACTG
CTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCTAGCGGAGCGATGCCCAACCAGGCG
CAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAAGGTGAAGGTGCTTGGATCTGGCGCT
TTTGGCACAGTCTACAAGGGCATCTGGATCCCTGATGGGGAGAATGTGAAAATTCCAGTG
GCCATCAAAGTGTTGAGGGAAAACACATCCCCCAAAGCCAACAAAGAAATCTTAGACGAA
GCATACGTGATGGCTGGTGTGGGCTCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTG
ACATCCACGGTGCAGCTGGTGACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTC
CGGGAAAACCGCGGACGCCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCC
AAGGGGATGAGCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAAC
GTGCTGGTCAAGAGTCCCAACCATGTCAAAATTACAGACTTCGGGCTGGCTCGGCTGCTG
GACATTGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCATCAAGTGGATGGCG
CTGGAGTCCATTCTCCGCCGGCGGTTCACCCACCAGAGTGATGTGTGGAGTTATGGTGTG
ACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATCCCAGCCCGGGAG
ATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCCCCCCATCTGCACCATTGAT
GTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGAATGTCGGCCAAGATTCCGG
GAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACCCCCAGCGCTTTGTGGTCATCCAG
AATGAGGACTTGGGCCCAGCCAGTCCCTTGGACAGCACCTTCTACCGCTCACTGCTGGAG
GACGATGACATGGGGGACCTGGTGGATGCTGAGGAGTATCTGGTACCCCAGCAGGGCTTC
TTCTGTCCAGACCCTGCCCCGGGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCTCA
TCTACCAGGAGTGGCGGTGGGGACCTGACACTAGGGCTGGAGCCCTCTGAAGAGGAGGCC
CCCAGGTCTCCACTGGCACCCTCCGAAGGGGCTGGCTCCGATGTATTTGATGGTGACCTG
GGAATGGGGGCAGCCAAGGGGCTGCAAAGCCTCCCCACACATGACCCCAGCCCTCTACAG
CGGTACAGTGAGGACCCCACAGTACCCCTGCCCTCTGAGACTGATGGCTACGTTGCCCCC
CTGACCTGCAGCCCCCAGCCTGAATATGTGAACCAGCCAGATGTTCGGCCCCAGCCCCCT
TCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCTGGTGCCACTCTGGAAAGGCCC
AAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCCTTTGGGGGTGCC
GTGGAGAACCCCGAGTACTTGACACCCCAGGGAGGAGCTGCCCCTCAGCCCCACCCTCCT
CCTGCCTTCAGCCCAGCCTTCGACAACCTCTATTACTGGGACCAGGACCCACCAGAGCGG
GGGGCTCCACCCAGCACCTTCAAAGGGACACCTACGGCAGAGAACCCAGAGTACCTGGGT
CTGGACGTGCCAGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07714</identifier>
            <name>Pkinase_Tyr</name>
          </pfam>
          <pfam>
            <identifier>PF00757</identifier>
            <name>Furin-like</name>
          </pfam>
          <pfam>
            <identifier>PF01030</identifier>
            <name>Recep_L_domain</name>
          </pfam>
          <pfam>
            <identifier>PF14843</identifier>
            <name>GF_recep_IV</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basal plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lateral loop</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>microvillus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ErbB-3 class receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein C-terminus binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein dimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein phosphatase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor signaling protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase I core binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane receptor protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enzyme linked receptor protein signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrous cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland involution</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>motor neuron axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myelination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of immature T cell proliferation in thymus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular junction development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oligodendrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peripheral nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of GTPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein targeting to membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase I promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase III promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of translation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of microtubule-based process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to axon injury</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle tissue development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sympathetic nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tongue development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>